nav





10/27/2014    Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons
 
10/23/2014    Generex / Antigen Express to Participate in 2014 BIO-Europe® Annual International Partnering Conference
 
10/21/2014    Generex Announces Publication of Ebola Vaccine White Paper by Antigen Express
 
10/7/2014    Generex Clarifies Utility of Antigen Express Technology for Potential Ebola Vaccine
 
9/3/2014    Generex / Antigen Express to Participate in BioPharm America™ 2014
 
8/6/2014    Generex Announces Publication of AE37 Prostate Cancer Vaccine Study
 
6/17/2014    Generex Announces Interview of Dr. Eric von Hofe, President of Antigen Express, Following Recent Keynote Presentation
 
6/12/2014    Generex/Antigen Express Announce Interview of MD Anderson's Dr. Elizabeth Mittendorf, Principal Investigator on Company's AE37 Phase IIb Breast Cancer Efficacy Trial
 
6/10/2014    Generex / Antigen Express to Participate in 2014 BIO International Convention
 
5/20/2014    Generex Announces Presentation of Primary Efficacy Data & Immunological Response from the Phase II Study of AE37 Cancer Vaccine at ASCO
 
4/23/2014    Generex Announces Antigen Express AE37 Breast Cancer Vaccine Abstract Presentations at ASCO 2014 Annual Meeting
 
3/26/2014    Generex/Antigen Express Announces Participation on Panel at Upcoming Cancer Immunotherapeutics Symposium
 
3/5/2014    Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza
 
2/27/2014    Generex Announces Publication of Biomarker Studies Related to the Antigen Express Novel Immunotherapeutic AE37 in Prostate Cancer Patients
 
2/12/2014    Generex Provides Update on Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
 
2/12/2014    Generex/Antigen Express Interview on Clear Channel Business Talk Radio DFW 1190AM by Host Michael Yorba - Wednesday, February 12, 2014
 
2/4/2014    Generex/Antigen Express "Stock News Now" Interview Available Online
 
1/13/2014    Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
 
1/9/2014    Generex Announces Selection of Antigen Express Technology for Keynote Presentation at 2014 TIDES Conference
 
1/6/2014    Generex/Antigen Express Announce Database Lock of AE37 Breast Cancer Vaccine Trial
 
11/18/2013    Antigen Express AE37 Breast Cancer Vaccine Update
 
8/20/2013    Generex Announces Publication of Follow-up Studies from Phase I Trial of Novel Immunotherapeutic in Prostate Cancer Patients
 
8/13/2013    Generex Announces Podium Presentation on Antigen Express Cancer Vaccine Strategy
 
8/12/2013    Generex Provides Call-In Details for Conference Call with Members of the Antigen Express Scientific Advisory Board
 
7/12/2013    Generex Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board
 
7/1/2013    Generex Announces Conference Call with Members of the Antigen Express Scientific Advisory Board
 
6/12/2013    Generex Announces Interview of MD Anderson's Dr. Elizabeth Mittendorf, Principal Investigator on Company's AE37 Phase IIb Breast Cancer Efficacy Trial
 
6/5/2013    Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients
 
5/31/2013    Positive Generex Data Underscores Cancer Immunotherapy Forecast Issued by Citi
 
5/22/2013    Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine.
 
2/7/2013    Generex Touts Pipeline Potential of Antigen Express Subsidiary
 
1/31/2013    Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
 
1/30/2013    Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
 
1/17/2013    Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
 
11/13/2012    Generex Provides Update on Company Initiatives Including the AE37 Breast Cancer Vaccine Program
 
9/20/2012    Generex Management Provides Update to Stockholders
 
9/13/2012    Generex Biotechnology Announces Presentation of Early Results Showing Activity of Cancer Vaccine in Patients with Triple Negative Breast Cancer
 
6/14/2012    Generex Announces Publication of Abstract at ASCO 2012 Showing Potential of Antigen Express AE37 Immunotherapeutic Cancer Vaccine Technology in Prostate Cancer
 
6/8/2012    Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
 
6/7/2012    Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
 
6/6/2012    Generex Announces ASCO 2012 Podium Presentation Showcasing Antigen Express AE37 Cancer Vaccine Technology
 
6/5/2012    Generex Announces Presentation of New Immune Response Data from AE37 Phase II Breast Cancer Trial at ASCO 2012
 
5/18/2012    Generex Augments Antigen Express Scientific Advisory Board
 
5/17/2012    Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
 
5/15/2012    Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
 
5/9/2012    Generex Announces Establishment of a Scientific Advisory Board for Antigen Express
 
5/8/2012    Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
 
4/3/2012    Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
 
2/27/2012    Generex Subsidiary Antigen Express to Present at Prestigious Cancer Immunotherapy Summit
 
2/1/2012    Generex Announces Patent Award for its Core Vaccine Technologies in Japan
 
1/17/2012    Generex Subsidiary Antigen Express Featured on SNN Stock News Now; Highlights Advantages of Ii-Key Platform Technology for Cancer Immunotherapy
 
1/3/2012    Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
 
12/21/2011    Generex Announces Airing of Antigen Express Breast Cancer Vaccine Segment on Bloomberg Television
 
12/20/2011    Generex Provides Update on Bloomberg TV Breast Cancer Vaccine Segment
 
12/19/2011    Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
 
12/14/2011    Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television
 
12/8/2011    Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS
 
11/21/2011    Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase 2 Clinical Data at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
 
10/6/2011    Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine-Thursday, October 6, 2011
 
9/21/2011    Antigen Express' AE37 Cancer Vaccine Featured in Scientific American
 
9/19/2011    Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
 
9/15/2011    Generex Provides Update on Spinout of Antigen Express
 
8/18/2011    Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program
 
7/11/2011    Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
 
6/15/2011    Generex Announces Appointment of CEO for Post-Spinout Antigen Express
 
4/4/2011    Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
 
3/30/2011    Generex Unveils Strategic Development Plan
 
2/3/2011    Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine
 
1/25/2011    Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
 
1/6/2011    Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer
 
12/6/2010    Generex Presents New Positive AE37 Phase II Breast Cancer Vaccine Data
 
11/10/2010    Generex Oncology Awarded Two IRS Therapeutic Discovery Project Grants
 
9/16/2010    Generex Announces Presentations of Novel Vaccine Strategies
 
9/2/2010    Generex Oncology Announces Consultancy of Dr. George E. Peoples, MD
 
8/5/2010    Generex Oncology Names Dr. Craig Eagle to its Scientific Advisory Board to Assist with its Proprietary Cancer Vaccines Program
 
7/13/2010    Generex Oncology Granted United States Patent for AE37 Peptide Vaccine
 
5/18/2010    GENEREX BIOTECHNOLOGY ANNOUNCES PUBLICATION OF NOVEL IMMUNOTHERAPEUTIC CANCER VACCINE RESULTS IN PATIENTS WITH PROSTATE CANCER
 
3/2/2010    Generex Subsidiary Antigen Express Receives Patent in China for Its Ii-Key Peptide Vaccine Technology
 
1/19/2010    Generex Makes Podium Presentation of Vaccine Technology Platform with Cancer & Influenza Updates at PepTalk 2010
 
11/23/2009    Generex Scientist Makes Presentation at National Influenza Congress
 
10/5/2009    Homeland Security TV Features Generex Executive to Discuss H1N1 Preparedness and Related Biological Security Issues
 
8/27/2009    Generex Biotechnology Corporation’s Synthetic Vaccine Platform Represented at International Swine Flu Conference
 
8/24/2009    Generex Biotechnology CEO Anna Gluskin Featured on BNN News to Discuss Potential for H1N1 Vaccine
 
8/5/2009    Generex Announces Publication of Pre-Clinical Studies Demonstrating Utility of Its Vaccine Platform for Addressing Pandemic Influenza
 
7/20/2009    GENEREX PUBLISHES RESULTS FROM PRE-CLINICAL STUDIES ON IMMUNOTHERAPEUTIC VACCINE FOR HPV-INDUCED CERVICAL CANCER
 
6/1/2009    Generex Presents Positive Results of Phase 1 Prostate Cancer Vaccine Trial at the American Society of Clinical Oncology
 
5/28/2009    Generex Scientist to Participate in Panel Discussion at Swine Influenza Symposium
 
5/26/2009    Generex Biotechnology Presents Platform Vaccine Technology At International Congress of Antibodies
 
4/21/2009    Generex Announces Agreement with the Immune Tolerance Network
 
4/20/2009    Generex Data Presented at American Association for Cancer Research 100th Annual Meeting
 
3/3/2009    Generex Biotechnology Announces Treatment of First Patient with its Novel Immunotherapeutic Vaccine
 
1/12/2009    Generex Biotechnology Announces Publication of Novel Immunotherapeutic Cancer Vaccine Studies
 
12/16/2008    Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration
 
12/11/2008    Generex Biotechnology Update On Novel Immunotherapeutic Vaccine to be Presented At San Antonio Breast Cancer Symposium
 
11/10/2008    Generex Biotechnology Corporations Antigen Express Subsidiary Featured in Technology Update and Value Focus Review Issued by Scimitar Equity, LLC
 
8/7/2008    Enrollment of breast and ovarian cancer patients commenced for combination therapy trial to include Generex Biotechnology’s novel immunotherapeutic vaccine
 
7/9/2008    Investigational New Drug Application Submitted On Behalf of Generex Biotechnology for Combination Immunotherapy Vaccine Trials
 
6/26/2008    Generex Biotechnology Expands Mayo Clinic Collaboration for Vaccine Studies
 
6/23/2008    A Shot in the Arm Against Breast Cancer
 
6/10/2008    Blood Test for Type-1 Diabetes Coming Soon
 
6/9/2008    Generex Biotechnology Presented Data At American Diabetes Association Scientific Sessions
 
6/3/2008    GENEREX BIOTECHNOLOGY PHASE I TRIAL RESULTS FOR NOVEL IMMUNOTHERAPY VACCINE IN BREAST CANCER PATIENTS PRESENTED AT ASCO
 
3/3/2008    Generex Biotechnology Extends Clinical Trial Agreement for Testing its Synthetic Avian Influenza Vaccine
 
1/22/2008    GENEREX BIOTECHNOLOGY ANNOUNCES CO-AUTHORSHIP OF PUBLICATIONS WITH JOHNS HOPKINS UNIVERSITY AND STALLERGENES S.A.
 
12/18/2007    Generex Biotechnology Awarded Patent in Japan
 
11/5/2007    FIRST PROSTATE CANCER PATIENTS TREATED IN A PHASE I CLINICAL TRIAL AS PART OF A COLLABORATION BETWEEN GENEREX BIOTECHNOLOGY AND THE SAINT SAVAS CANCER HOSPITAL
 
10/9/2007    Generex Biotechnology RNAi-based Tumor Vaccine Set for Trials in China to be Presented at Leading International Oncology Meeting
 
8/22/2007    GENEREX BIOTECHNOLOGY TO COLLABORATE WITH LEADING INVESTIGATOR AT ROCHESTER UNIVERSITY ON PANDEMIC AVIAN INFLUENZA VACCINE
 
8/22/2007    Mass. firm taps UR expert to develop vaccine
 
7/31/2007    THE INTERNATIONAL JOURNAL OF CANCER PUBLISHES STUDIES ON GENEREX BIOTECHNOLOGY'S ANTI-CANCER ACTIVITY OF ITS IMMUNOTHERAPEUTIC VACCINE
 
6/14/2007    Generex Biotechnology Awarded New U.S. Patents for Its Core Vaccine Technologies
 
5/24/2007    Generex Biotechnology Vaccine Strategy Presented at International Conference in London
 
4/16/2007    GENEREX BIOTECHNOLOGY VACCINE DEVELOPMENT PROGRAMS PRESENTED AT THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH
 
3/27/2007    Generex Executive Discusses RNAi Platform in Online Interview
 
3/26/2007    GENEREX BIOTECHNOLOGY TO TEST NOVEL RNAi-BASED IMMUNE-RESPONSE STRATEGY IN CANCER PATIENTS
 
3/19/2007    GENEREX SCIENTIST TO PRESENT ON THE STATUS OF INFLUENZA VACCINE DEVELOPMENT AT NATIONAL CONFERENCE
 
2/13/2007    GENEREX BIOTECHNOLOGY EXTENDS SCOPE OF U.S. PATENT PROTECTION FOR VACCINE TECHNOLOGY
 
2/5/2007    VOLUNTEERS SELECTED FOR HUMAN CLINICAL TRIAL OF GENEREX BIOTECHNOLOGY’S SYNTHETIC AVIAN INFLUENZA VACCINE
 
2/1/2007    GENEREX BIOTECHNOLOGY TO INITIATE PHASE II CLINICAL TRIALS IN BREAST CANCER PATIENTS IN COLLABORATION WITH UNITED STATES MILITARY’S CANCER INSTITUTE
 
12/14/2006    Clinical Trial Results from Cancer Vaccine being developed by Generex Biotechnology Subsidiary to be presented at San Antonio Breast Cancer Symposium
 
11/6/2006    GENEREX BIOTECHNOLOGY TO BEGIN THE FIRST HUMAN CLINICAL TRIAL OF AVIAN INFLUENZA VACCINE
 
11/2/2006    GENEREX BIOTECHNOLOGY SPONSORS EPISODE OF MEDICAL MISSIONS FOR CHILDREN PLAIN TALK ABOUT HEALTH PROGRAM ON AVIAN INFLUENZA
 
10/3/2006    GENEREX BIOTECHNOLOGY PUBLISHES STUDIES DEMONSTRATING ANTI-TUMOR POTENTIAL OF IMMUNOTHERAPEUTIC VACCINE
 
8/8/2006    GENEREX BIOTECHNOLOGY ANNOUNCES EXPANSION OF ANTIGEN EXPRESS CANCER TRIALS TO INCLUDE PROSTATE CANCER PATIENTS
 
6/8/2006    GENEREX BIOTECHNOLOGY ANNOUNCES PRESENTATION OF INTERIM BREAST CANCER TRIALS RESULTS AND BIRD FLU VACCINE STRATEGY
 
3/14/2006    Generex Biotechnology to Present Its Avian Influenza Vaccine Program at DNA Forum in London
 
2/27/2006    Generex Biotechnology to Present Pandemic Influenza Vaccine Program at Bird Flu Summit in Washington, D.C.
 
2/13/2006    GENEREX BIOTECHNOLOGY COMPLETES POSITIVE PRE-IND MEETING WITH FDA FOR ITS AVIAN FLU VACCINE
 
1/25/2006    GENEREX BIOTECHNOLOGY ANNOUNCES INTERIM RESULTS OF CLINICAL BREAST CANCER TRIALS
 
1/23/2006    GENEREX BIOTECHNOLOGY ANNOUNCES FDA PRE-IND MEETING SCHEDULED FOR THE AVIAN FLU VACCINE
 
11/22/2005    GENEREX BIOTECHNOLOGY AUGMENTS REGULATORY TEAM WITH ENGAGEMENT OF REGULATORY AFFAIRS CONSULTANT
 
11/17/2005    GENEREX BIOTECHNOLOGY RETAINS RUBENSTEIN PUBLIC RELATIONS
 
11/17/2005    GENEREX BIOTECHNOLOGY RETAINS WASHINGTON, D.C. – BASED LOBBYIST TO PURSUE OPPORTUNITIES FOR ORAL INSULIN & ITS AVIAN FLU VACCINE
 
11/9/2005    GENEREX BIOTECHNOLOGY PROPOSES COLLABORATIONS IN CHINA FOR THE CO-DEVELOPMENT OF A NOVEL VACCINE FOR PANDEMIC AVIAN INFLUENZA
 
11/4/2005    GENEREX SCIENTIST PRESENTS RESULTS OF PANDEMIC INFLUENZA VACCINE PROGRAM AT WASHINGTON CONFERENCE HIGHLIGHTING STRATEGIC ADVANCES IN VACCINES
 
11/2/2005    GENEREX PANDEMIC INFLUENZA VACCINE PROGRAM TO BE PRESENTED AT NOVEL VACCINE CONCEPTS CONFERENCE IN WASHINGTON DC
 
10/27/2005    GENEREX BIOTECHNOLOGY PRESENTS PROPOSAL TO INTERESTED U.S. SENATORS TO ACCELERATE DEVELOPMENT OF NOVEL PANDEMIC AVIAN INFLUENZA VACCINE
 
10/19/2005    GENEREX BIOTECHNOLOGY TO ACCELERATE DEVELOPMENT OF VACCINE FOR PANDEMIC AVIAN INFLUENZA
 
9/15/2005    GENEREX BIOTECHNOLOGY PRESENTS IMMUNOTHERAPEUTICS STUDY RESULTS AT THE 41ST ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES
 
9/6/2005    GENEREX BIOTECHNOLOGY RECEIVES AUSTRALIAN PATENT
 
8/23/2005    MICE WITH HUMAN ANTIGEN PRESENTING MOLECULES DEMONSTRATE STRONG RESPONSES TO NOVEL MELANOMA PEPTIDE VACCINE WHICH IS DESTINED FOR CLINICAL TRIALS
 
8/16/2005    PANDEMIC INFLUENZA VACCINE DEVELOPMENT ACCELERATED AT GENEREX BIOTECHNOLOGY WITH HIRE OF ACCOMPLISHED SENIOR SCIENTIST
 
6/22/2005    GENEREX BIOTECHNOLOGY BEGINS RESEARCH COLLABORATION ON NOVEL ALLERGY THERAPY WITH MAJOR EUROPEAN COMPANY
 
5/11/2005    GENEREX BIOTECHNOLOGY IMMUNE-RESPONSE STRATEGY TO BE TESTED FOR USE AGAINST CANCER
 
4/28/2005    GENEREX BIOTECHNOLOGY BEGINS TESTING NEW VACCINE FOR BREAST CANCER PATIENTS
 
4/26/2005    GENEREX BIOTECHNOLOGY RECEIVES AUSTRALIAN PATENT FOR NOVEL VACCINE TECHNOLOGY
 
4/21/2005    GENEREX BIOTECHNOLOGY COLLABORATOR REPORTS AN ADVANCE IN INTRA-TUMOR GENE THERAPY FOR CANCER
 
3/22/2005    Generex Biotechnology's Subsidiary Antigen Express Initiates Clinical Trials in Patients with Her-2/neu Positive Breast Cancer
 
1/27/2005    United States Awards Patent to Antigen Express subsidiary of Generex Biotechnology
 
11/2/2004    POTENT PRECLINICAL EFFECT OF NOVEL MELANOMA PEPTIDE VACCINE REPORTED AT THE SEVENTH INTERNATIONAL ANTICANCER CONFERENCE IN CORFU, GREECE
 
10/12/2004    GENEREX BIOTECHNOLOGY PRESENTS INFORMATION AT THE EUROCONFERENCE VACCINES 3 MEETING OF THE PASTEUR INSTITUTE IN PARIS ON THE USE OF NOVEL PEPTIDE VACCINE FOR MELANOMA
 
10/7/2004    Dr. Eric von Hofe appointed Generex VP for Product Development & Scientific Affairs
 
9/28/2004    GENEREX BIOTECHNOLOGY ESTABLISHES CRADA WITH THE UNIFORMED SERVICES UNIVERSITY AND THE HENRY M. JACKSON FOUNDATION FOR NOVEL HER-2/NEU VACCINE STUDIES AND CLINICAL TRIALS AT WALTER REED ARMY MEDICAL CENTER IN PATIENTS WITH BREAST CANCER
 
9/15/2004    GENEREX BIOTECHNOLOGY TESTS NOVEL VACCINE FOR MELANOMA WITH CLINICIAN AT FRED HUTCHINSON CANCER RESEARCH CENTER
 
8/18/2004    Generex Biotechnology Expands HIV vaccine efforts with leading MGH Investigator
 
6/22/2004    Generex Biotechnology Presents Potential Uses of RpaidmistR Technology in Transmucosal Vaccines at Merieux Conference in France
 
6/1/2004    Generex Biotechnology Initiates late Pre-Clinical Studies to Prepare for Vaccine Trials in Patients with Her-2/neu Positive Ovarian Cancer
 
5/13/2004    GENEREX BIOTECHNOLOGY RECEIVES KEY JAPANESE PATENT FOR NOVEL TECHNOLOGY TO ENHANCE T HELPER CELL RECOGNITION OF CANCER AND BIOTERRORISM ANTIGENS
 
4/14/2004    INVITED CANCER TREATMENT REVIEW DESCRIBES NOVEL IN SITU CANCER VACCINE TO CURE RECURRENT CANCER
 
4/6/2004    GENEREX BIOTECHNOLOGY CORPORATION REPORTS SIGNIFICANT ADVANCE IN CANCER
 
3/3/2004    Generex Biotechnology Working to Develop Diagnostic Kit for Early Detection
 
2/9/2004    Generex Appoints Dr. Douglas Powell as Director of Immunobiology
 

 
 
Home | Company | People | Technology | Therapeutic Focus | Business Development | News | Contact
© 2004 Antigen Express | Website designed by NRG Networks